A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

Learn more about:
Related Clinical Trial
Data Analysis of Protocol 04-N-0188: Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm Mexiletine for the Treatment of Focal Dystonia A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm An RCT of a Patient-initiated Treatment Service for BEB and HFS Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Photic Blink Reflex in People With Blepharospasm and Increased Blinking IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Blepharospasm Short Interval Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm Brain Changes in Blepharospasm Blepharospasm Patient Survey for Patients With Blepharospasm A Mechanical Device for Blepharospasm Blepharospasm Tools Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Brief Title

A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm


Brief Summary

      This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins
      BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of
      Cervical Dystonia and Blepharospasm in clinical practice.
    



Study Type

Observational


Primary Outcome

Dose of Botulinum Toxin Used to Treat Cervical Dystonia

Secondary Outcome

 Number of Participants With Adverse Events

Condition

Cervical Dystonia

Intervention

No Intervention

Study Arms / Comparison Groups

 BOTOX®
Description:  Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

48

Start Date

January 2013

Completion Date

July 2013

Primary Completion Date

July 2013

Eligibility Criteria

        Inclusion Criteria:

          -  confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at
             least 2 years

          -  treatment with Xeomin® and BOTOX® for at least 1 year each

        Exclusion Criteria:

          -  having a neuromuscular junction transmission disorder or taking any medications that
             could affect neuromuscular junction transmission

          -  previous surgical procedure involving bone or muscle for the management of cervical
             dystonia or blepharospasm
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Medical Director, , 

Location Countries

Norway

Location Countries

Norway

Administrative Informations


NCT ID

NCT01814774

Organization ID

TRU2011


Responsible Party

Sponsor

Study Sponsor

Allergan


Study Sponsor

Medical Director, Study Director, Allergan


Verification Date

June 2014